Skip to content

Released Aug 5, 2022, before the open

10-Q filed Aug 5, 2022, 36 days after period end · 0001764013-22-000085

Q1 2023 · 10-Q
Revenue—
Net Income-$40.37MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.35N/M vs Q1 2022no prior Q4 2022 on file
Operating Cash Flow-$65,819,000N/M
Free Cash Flowderived-$65,861,000N/M

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2019Q1 2018
Net Income-$40.37M-$30.47M-$20.06M-$4.37M
EPS Diluted-$0.35-$0.31-$0.52—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR